$IMNN

Eylward Susan sold $2K of IMNN

Eylward Susan (General Counsel and Corp Sec) sold 920 shares of Imunon, Inc. (IMNN) at $1.88 on 2026-07-06.

Original reporting
SEC EDGAR · Eylward Susan
Published Jul 7, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 7:59 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IMNN
Neutral
low confidence
Mentioned
$IMNN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

This provides a fresh datapoint on insider selling activity, but it does not include earnings, guidance, clinical, regulatory, or deal information that would change valuation drivers.

02

Market read

Traders may monitor IMNN for follow-on insider activity, but the filing alone is unlikely to drive a major repricing.

03

What to watch

The absence of a 10b5-1 plan can raise attention, but the article provides no context on motivations, taxes, or prior planned sales.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-07, transaction dated 2026-07-06

Background

The article is a SEC Form 4 insider transaction disclosure for Imunon, Inc. (IMNN).

Company-level read

Ticker impact

$IMNNNeutralLow confidence
Context

Imunon disclosed an insider open-market sale by General Counsel Susan Eylward of 920 shares at $1.88 on 2026-07-06.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless accompanied by other disclosures.

Evidence & confidence

Form 4 insider sales are common and this transaction is small relative to typical market moves, with no 10b5-1 plan and no accompanying fundamental catalyst in the text.

Market effects

No sector-wide implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification or personal liquidity needs and does not necessarily reflect a negative view of the business.

Key entities

  • Imunon, Inc.

    Subject of the Form 4 insider sale disclosure (IMNN).

  • Eylward Susan

    General Counsel and Corp Sec who sold 920 shares at $1.88 on 2026-07-06.

Related articles

$IMNNMed

EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study - Im

Imunon Inc. (NASDAQ:IMNN) updated its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said site activation and enrollment are ahead of forecasts, with full enrollment expected by Q2 2029. It reported no cytokine release syndrome or serious immune-related adverse events and noted two interim analyses that could support an early BLA. Shares rose 1.95% to $1.57 premarket.

$IMNNMed

Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

IMUNON (Nasdaq: IMNN) provided an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said enrollment is ahead of plan, with a study rate of about 0.5 patients per site per month versus 0.3 planned, and it now expects completion in Q2 2029. It reported no cytokine release syndrome and comparable safety versus control.

$IMNNMedAI 9/10

Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)

Imunon Inc. (NASDAQ:IMNN) said it secured a $10 million financing package to advance its Phase 3 OVATION 3 ovarian cancer trial of IMNN-001. The company will receive $2.5 million via 250 non-redeemable, non-convertible preferred shares and about $7.72 million through two secured promissory notes at 8% and 5% interest, maturing in 18 months. Imunon cited updated Phase 2 survival data.